As Introduced

133rd General Assembly Regular Session 2019-2020

S. B. No. 231

Senators Craig, Antonio

Cosponsors: Senators Thomas, Williams, Yuko

A BILL

| То | require | the Att | orney | General | to | investi | Ĺga | ate | 1 |
|----|---------|---------|-------|---------|-----|---------|-----|---------|---|
| | insulin | pricing | and p | repare | and | submit | а | report. | 2 |

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

| Section 1. (A) The Attorney General shall investigate the | 3 |
|--|----|
| pricing of prescription drugs containing insulin. The purpose of | 4 |
| the investigation is to ensure adequate consumer protections in | 5 |
| the pricing and sale of insulin used to treat diabetes and to | 6 |
| determine if additional consumer protections are needed. | 7 |
| (B)(1) As part of the investigation, the Attorney General | 8 |
| shall compile and analyze information from companies engaged in | 9 |
| the manufacture or sale of prescription insulin drugs. The | 10 |
| information shall relate to company business practices, company | 11 |
| organization, drug pricing data and reports, and any other | 12 |
| information the Attorney General finds relevant to the | 13 |
| investigation. The Attorney General also shall consider any | 14 |
| publicly available data or information concerning drug pricing | 15 |
| generally and insulin pricing specifically. | 16 |
| (2) If necessary to meet the requirements of this section, | 17 |
| the Attorney General may issue one or more civil investigative | 18 |

S. B. No. 231
As Introduced

| demands requiring any of the following to furnish to the | 19 | |
|--|----|--|
| Attorney General materials, answers, data, or other relevant | 20 | |
| information: state departments, health plan issuers, pharmacy | 21 | |
| benefit managers, drug manufacturers, or pharmacies. | 22 | |
| (3) Any materials, answers, data, or other relevant | 23 | |
| information furnished to the Attorney General as part of the | 24 | |
| investigation are confidential, shall not be considered public | 25 | |
| records under section 149.43 of the Revised Code, and shall be | 26 | |
| used by the Attorney General only as necessary to meet the | 27 | |
| requirements of this section. | 28 | |
| (C)(1) Not later than eighteen months after the effective | 29 | |
| date of this section, the Attorney General shall prepare and | 30 | |
| submit to the following a report detailing its findings: | 31 | |
| (a) The Governor; | 32 | |
| (b) The Superintendent of Insurance; | 33 | |
| (c) The Chairpersons and Ranking Minority Members of the | 34 | |
| committees of the General Assembly having primary jurisdiction | 35 | |
| over issues relating to civil and criminal justice; | 36 | |
| (d) The Chairpersons and Ranking Minority Members of the | 37 | |
| committees of the General Assembly having primary jurisdiction | 38 | |
| over issues relating to health. | 39 | |
| (2) The report shall include all of the following: | 40 | |
| (a) A summary of current insulin pricing practices and | 41 | |
| variables that contribute to insulin pricing by drug | 42 | |
| manufacturers, health plan issuers, pharmacy benefit managers, | | |
| and pharmacies; | 44 | |
| (b) Recommendations for controlling and preventing the | 45 | |
| overpricing of prescription insulin; | 46 | |

| S. B. No. 231 As Introduced | Page 3 |
|--|--------|
| (c) Recommendations for improving Ohio's consumer | 47 |
| protection laws to prevent deceptive sales practices involving | 48 |
| the pricing and sale of prescription insulin; | 49 |
| (d) Any other information the Attorney General finds | 50 |
| relevant, except for confidential information as described in | 51 |
| division (B)(3) of this section. | 52 |